Target intelligence / Profile preview

Fanconi anemia group B protein (FANCB)

Target
FANCB
Molecular classification
Enzyme (E3 ubiquitin ligase complex component), DNA repair protein, Protein complex subunit (FA core complex), Other (structural scaffold of ubiquitin ligase complex)
01

Overview

Fanconi anemia group B protein (FANCB) is a core component of the Fanconi anemia (FA) DNA repair pathway, involved in repairing DNA interstrand crosslinks during DNA replication[2][3]. FANCB forms a central part of the FA core complex, assembling with FAAP100 and FANCL to create the catalytic E3 ubiquitin ligase subcomplex critical for the monoubiquitination of FANCD2 and FANCI[1][2]. This modification is essential for recruiting downstream nucleases and repair proteins to damaged DNA. Mutations in FANCB cause a severe, X-linked form of Fanconi anemia, leading to congenital abnormalities, bone marrow failure, cancer predisposition, and infertility, particularly in males[2]. FANCB does not appear to be a direct target for any approved drugs, but its essential role in DNA repair means its dysfunction markedly affects cell survival in response to DNA crosslinking agents[3].

Other names
Protein FACBFAAP95FAAP90FABFLJ34064Fanconi anemia-associated polypeptide of 95 kDaFanconi anemia complementation group B
02

Mechanism of action

As part of the FA core complex, FANCB enables E3 ubiquitin ligase activity, critical for monoubiquitinating FANCD2 and FANCI, which is a key step in DNA interstrand crosslink repair[1][2][3]

03

Biological functions

DNA repairMonoubiquitination of FANCD2 and FANCIMaintenance of genome stabilitySpermatogenesis (essential for meiosis and germ cell development)Regulation of cell cycle in response to DNA damage
04

Disease associations

Cancer (mainly increased risk due to genomic instability)Bone marrow failure (as seen in Fanconi anemia)Congenital abnormalities (notably, VACTERL-H association)Other (hypersensitivity to DNA crosslinking agents, infertility)
05

Safety considerations

Severe congenital defects and bone marrow failure with FANCB deficiency[2]High cancer risk due to impaired DNA repairTherapeutic approaches targeting DNA repair may worsen cytopenia or increase toxicity
06

Interacting drugs

cisplatin

2 more in the full profile.

07

Biomarkers

FANCB mutation (for Fanconi anemia diagnosis)FANCD2/FANCI monoubiquitination status (reflects FA core complex function)

Beyond the preview

Go deeper on Fanconi anemia group B protein (FANCB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fanconi anemia group B protein (FANCB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call